DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors ( nAChR ) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions [2].
In Vivo, M-R@siC-NPs (containing DSPE-PEG2000-RVG29) (80 μg/mL; intraperitoneal) effectively suppress hippocampal astrocyte activation, reduce neuroinflammation, and improve motor coordination and spatial memory in HIBD neonatal mice[1]. DSPE-PEG2000-RVG29 (10 mol%; retro-orbital injection) modification enhances brain targeting of lipopolyplexes, resulting in increased and localized transgene expression in the mouse striatum and substantia nigra[2].
In Vitro, DSPE-PEG2000-RVG29-containing M-R@siC-NPs exhibit uniform size distribution, near-neutral surface charge, efficient siRNA loading, and long-term structural stability in biological media[1]. DSPE-PEG2000-RVG29-containing M-R@siC-NPs (20-120 μg/mL; 24 h) show low cytotoxicity in primary astrocytes at concentrations up to 80 μg/mL, with reduced viability at higher doses[1]. DSPE-PEG2000-RVG29-functionalized BAELPP (0.5 μg DNA equivalent per well; 24 h/48 h) achieves high transfection efficiency in SH-SY5Y human neuroblastoma cells with low cytotoxicity[2].
References:
[1]. Dang Y, et al. Dual-Modified Mannose/RVG29 Peptide-Functionalized Lipid Nanoparticles Loaded With circHIPK2 siRNA Ameliorate Hypoxic-Ischemic Brain Damage in Neonatal Mice by Suppressing Astrocyte Activation. J Integr Neurosci. 2025;24(12):45212.
[2]. Yujing Zhang, et al. Advancing Parkinson's Prevention: Brain-Specific Lipopolyplex Delivery of Gdnf as a Neuroprotective Gene Therapy. 40 Pages Posted: 8 Jul 2025.
In Vivo, M-R@siC-NPs (containing DSPE-PEG2000-RVG29) (80 μg/mL; intraperitoneal) effectively suppress hippocampal astrocyte activation, reduce neuroinflammation, and improve motor coordination and spatial memory in HIBD neonatal mice[1]. DSPE-PEG2000-RVG29 (10 mol%; retro-orbital injection) modification enhances brain targeting of lipopolyplexes, resulting in increased and localized transgene expression in the mouse striatum and substantia nigra[2].
In Vitro, DSPE-PEG2000-RVG29-containing M-R@siC-NPs exhibit uniform size distribution, near-neutral surface charge, efficient siRNA loading, and long-term structural stability in biological media[1]. DSPE-PEG2000-RVG29-containing M-R@siC-NPs (20-120 μg/mL; 24 h) show low cytotoxicity in primary astrocytes at concentrations up to 80 μg/mL, with reduced viability at higher doses[1]. DSPE-PEG2000-RVG29-functionalized BAELPP (0.5 μg DNA equivalent per well; 24 h/48 h) achieves high transfection efficiency in SH-SY5Y human neuroblastoma cells with low cytotoxicity[2].
References:
[1]. Dang Y, et al. Dual-Modified Mannose/RVG29 Peptide-Functionalized Lipid Nanoparticles Loaded With circHIPK2 siRNA Ameliorate Hypoxic-Ischemic Brain Damage in Neonatal Mice by Suppressing Astrocyte Activation. J Integr Neurosci. 2025;24(12):45212.
[2]. Yujing Zhang, et al. Advancing Parkinson's Prevention: Brain-Specific Lipopolyplex Delivery of Gdnf as a Neuroprotective Gene Therapy. 40 Pages Posted: 8 Jul 2025.